Clinical Trial Update: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on sonelokimab for active psoriatic arthritis in patients with inadequate response to anti-TNFα therapy; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Sonelokimab (sonelokimab)

Snippet

Sponsor: MoonLake Immunotherapeutics AG | Conditions: Arthritis, Psoriatic | Phase 3 | Status: RECRUITING